|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Other receivable | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| NON-CURRENT ASSETS | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Accrued expenses - related party | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Convertible note payable, net of debt discount | ||||||||||||||||||||
| Notes payable - related party | ||||||||||||||||||||
| Shares to be issued | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Convertible note payable, net of debt discount, non-current portion | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively; liquidation preference of $0 and $0, respectively | ||||||||||||||||||||
| STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| Preferred shares | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Common stock, $0.001 par value; 7,500,000,000 shares authorized at June 30,2026 and December 31, 2025; 722,506,634 and 486,895,359 shares issued and outstanding as of June 30,2026, and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| TOTAL STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| Convertible note payable, net of debt discount | ||||||||||||||||||||
Loading...
